What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone. When food enters the digestive system, the gut releases GLP-1, which signals the pancreas to produce insulin, suppresses glucagon secretion, slows gastric emptying, and communicates satiety to the brain.
Synthetic GLP-1 agonists amplify these effects far beyond what natural GLP-1 can achieve. They have been FDA-approved for type 2 diabetes management since 2005 (exenatide/Byetta) and for chronic weight management since 2014 (liraglutide/Saxenda), with dramatically more effective agents introduced since 2021.
- GLP-1 MonoSemaglutide (Ozempic, Wegovy)Single incretin: targets GLP-1 receptor only
- GIP/GLP-1 DualTirzepatide (Mounjaro, Zepbound)Dual incretin: activates both GIP and GLP-1 receptors
- GIP/GLP-1/Glucagon TripleRetatrutide (Phase III)Triple agonist: adds glucagon receptor for increased energy expenditure
Why Dose Escalation Is Required
GLP-1 agonists require gradual dose escalation over 4-20 weeks to minimize gastrointestinal side effects (primarily nausea, vomiting, diarrhea, and constipation). Starting at the full therapeutic dose often causes intolerable GI distress and leads to treatment discontinuation.
The reason: GLP-1 receptor activation significantly slows gastric emptying (the rate food leaves the stomach). At low doses, the body gradually adapts to this slower transit time. Jumping directly to a high dose overwhelms the GI system before adaptation can occur.
Key principle: Each dose step is maintained for 4 weeks minimum before escalating. Some clinicians extend to 8 weeks if side effects persist. Escalation should not proceed until current-dose side effects are manageable.
Dose escalation also allows clinicians to find the minimum effective dose for each patient. Not everyone needs the maximum dose: many patients achieve satisfactory results at intermediate dose steps, with fewer side effects and lower cost.
Semaglutide: Wegovy & Ozempic Schedules
Semaglutide has a ~7-day half-life, making once-weekly injection convenient and effective. Two FDA-approved formulations exist with different indication-specific dose targets:
Wegovy (Weight Management)
| When | Dose | Note |
|---|---|---|
| Weeks 1-4 | 0.25 mg | |
| Weeks 5-8 | 0.5 mg | |
| Weeks 9-12 | 1.0 mg | |
| Weeks 13-16 | 1.7 mg | |
| Week 17+ | 2.4 mg | (maintenance) |
Ozempic (Type 2 Diabetes)
| When | Dose | Note |
|---|---|---|
| Weeks 1-4 | 0.25 mg | |
| Weeks 5-8 | 0.5 mg | |
| Week 9+ | 1.0 mg | (up to 2.0 mg) |
The weight management dose target (2.4 mg) is significantly higher than the diabetes dose (1.0-2.0 mg), reflecting the STEP clinical trial findings that higher doses produce greater weight loss. Average weight loss in the STEP 1 trial was 14.9% at the 2.4 mg dose over 68 weeks.
Tirzepatide: Mounjaro & Zepbound Schedules
Tirzepatide is a dual GIP/GLP-1 receptor agonist with a ~5-day half-life. By activating both incretin receptors, it achieves greater glycemic control and weight loss than GLP-1-only agents in head-to-head trials.
Mounjaro / Zepbound Schedule
| When | Dose | Note |
|---|---|---|
| Weeks 1-4 | 2.5 mg | |
| Weeks 5-8 | 5.0 mg | |
| Weeks 9-12 | 7.5 mg | (optional step) |
| Weeks 13-16 | 10.0 mg | |
| Weeks 17-20 | 12.5 mg | (optional step) |
| Week 21+ | 15.0 mg | (maintenance) |
The SURMOUNT-1 trial showed tirzepatide at the maximum dose achieved 22.5% mean weight loss over 72 weeks, the largest weight reduction seen in a Phase III obesity trial at the time of publication.
Retatrutide: The Triple Agonist
Retatrutide (LY3437943) is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor activation adds thermogenesis (increased energy expenditure) on top of the appetite suppression and insulin secretion. Half-life: ~6 days.
Retatrutide Phase II Trial Arms (once weekly, 48 weeks)
| When | Dose | Note |
|---|---|---|
| 1 mg arm | 1 mg | |
| 4 mg arms | Start 2 or 4 mg | |
| 8 mg arms | Start 2 or 4 mg | |
| 12 mg arm | Start 2 mg |
Phase II results showed up to 24.2% mean weight loss at the 12 mg dose over 48 weeks (PMID 37366315). In the phase 3 TRIUMPH-1 trial, 12 mg once a week lowered body weight 25.0% at 80 weeks, versus 3.9% on placebo (PMID 42814954). Retatrutide is not FDA-approved.
Oral Semaglutide (Rybelsus)
Rybelsus is the oral formulation of semaglutide, FDA-approved for type 2 diabetes. It uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as an absorption enhancer to allow the peptide to survive stomach acid and be absorbed through the gastric lining.
Rybelsus Dose Escalation
| When | Dose | Note |
|---|---|---|
| Days 1-30 | 3 mg | daily (starter dose, not therapeutic) |
| Days 31-60 | 7 mg | daily |
| Day 61+ | 14 mg | daily (maintenance) |
Important: Oral semaglutide must be taken on an empty stomach with no more than 4 oz (120 mL) of plain water. Wait at least 30 minutes before eating, drinking, or taking other oral medications. Food significantly reduces absorption.
Key difference: The oral bioavailability of semaglutide is only about 1% compared to subcutaneous injection, which is why the label doses for tablets (Rybelsus 3-14 mg/day; Wegovy tablets up to 25 mg/day) are much higher than the injected doses (Wegovy 0.25-2.4 mg/week, up to 7.2 mg). In trials, oral semaglutide 25 mg a day lowered body weight 13.6% at 64 weeks (OASIS 4, PMID 40934115) and 50 mg a day, which is not approved, 15.1% at 68 weeks (OASIS 1, PMID 37385278).
Reconstituting Compounded GLP-1 Peptides
Compounded semaglutide and tirzepatide typically come as lyophilized powder in vials of 3 mg, 5 mg, or 10 mg. Unlike brand-name auto-injectors (which are pre-mixed), compounded versions require reconstitution with bacteriostatic water.
The reconstitution math is identical to any other peptide: concentration equals vial size divided by water volume. Use our Reconstitution Calculator for instant results.
| Vial | Water | Conc. | 0.25 mg dose | 1.0 mg dose | 2.4 mg dose |
|---|---|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 10 units | 40 units | 96 units |
| 5 mg | 1 mL | 5 mg/mL | 5 units | 20 units | 48 units |
| 3 mg | 1 mL | 3 mg/mL | 8.3 units | 33.3 units | 80 units |
| 10 mg | 2 mL | 5 mg/mL | 5 units | 20 units | 48 units |
Calculating Syringe Units for Each Dose Step
Units = Dose (mg) ÷ Concentration (mg/mL) × 100
Example for Wegovy schedule with 5 mg / 2 mL reconstitution (2.5 mg/mL):
| Phase | Dose | Calculation | Draw | Syringe |
|---|---|---|---|---|
| Month 1 | 0.25 mg | 0.25 ÷ 2.5 × 100 | 10 units | 30u syringe |
| Month 2 | 0.5 mg | 0.5 ÷ 2.5 × 100 | 20 units | 30u syringe |
| Month 3 | 1.0 mg | 1.0 ÷ 2.5 × 100 | 40 units | 50u syringe |
| Month 4 | 1.7 mg | 1.7 ÷ 2.5 × 100 | 68 units | 100u syringe |
| Maintenance | 2.4 mg | 2.4 ÷ 2.5 × 100 | 96 units | 100u syringe |
Managing Side Effects During Escalation
The most common side effects of GLP-1 agonists are gastrointestinal. They typically peak during the first 1-2 weeks of each new dose level and diminish with continued use.
- NauseaEat smaller meals, avoid greasy/spicy food, stay hydrated. Usually resolves within 1-2 weeks.
- ConstipationIncrease fiber intake, drink more water, consider osmotic laxatives (PEG 3350).
- Injection site reactionsRotate injection sites between abdomen, thigh, and upper arm. Apply ice before injection.
- FatigueCommon during first week of escalation. Ensure adequate protein intake (≥1 g/kg) and hydration.
- Acid reflux / GERDElevated GLP-1 slows gastric emptying, which can worsen reflux. Sleep with upper body elevated; avoid eating 3+ hours before bed.
- Hair thinningReported in some patients during rapid weight loss. Often related to caloric/protein deficit rather than the drug itself. Ensure ≥1.2 g protein/kg daily.
Drug Interactions & Contraindications
GLP-1 agonists slow gastric emptying, which can affect the absorption timing of oral medications taken at the same time. Key interactions to be aware of:
| Drug | Note |
|---|---|
| Oral contraceptives | Delayed absorption may reduce efficacy. Take 1 hour before or wait until GLP-1 side effects stabilize. |
| Sulfonylureas / Insulin | Increased hypoglycemia risk. Dose reduction of sulfonylurea or insulin is often needed when starting GLP-1 therapy. |
| Levothyroxine | Take on empty stomach 30-60 min before any food or GLP-1 injection. Monitor TSH levels. |
| Warfarin / Anticoagulants | Monitor INR more frequently during dose escalation as absorption changes may affect warfarin blood levels. |
Contraindications: GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). They should not be used with other GLP-1 receptor agonists. Do not use in pregnancy.
Half-Life Comparison Table
| Peptide | Half-Life | Type | Max Dose | Route |
|---|---|---|---|---|
| Semaglutide (injectable) | ~7 days | GLP-1 mono | 7.2 mg/week (Wegovy label) | SubQ |
| Semaglutide (oral) | ~7 days | GLP-1 mono | 25 mg/day (Wegovy tablets label) | Oral |
| Tirzepatide | ~5 days | GIP/GLP-1 dual | 15 mg/week (Zepbound label) | SubQ |
| Retatrutide | ~6 days | GIP/GLP-1/GCG triple | 12 mg/week in trials (not approved) | SubQ |
| Liraglutide | ~13 hours | GLP-1 mono | 3 mg/day (Saxenda label) | SubQ |
| Exenatide (Byetta) | ~2.4 hours | GLP-1 mono | 10 mcg twice daily (Byetta label) | SubQ |
Clinical Weight Loss Data
| Trial | Drug | Dose | Duration | Weight Loss |
|---|---|---|---|---|
| STEP 1 (PMID 33567185) | Semaglutide | 2.4 mg/wk | 68 weeks | -14.9% |
| SURMOUNT-1 (PMID 35658024) | Tirzepatide | 15 mg/wk | 72 weeks | -20.9% |
| Phase II (PMID 37366315) | Retatrutide | 12 mg/wk | 48 weeks | -24.2% |
| SCALE (PMID 26132939) | Liraglutide | 3.0 mg/day | 56 weeks | -8.4 kg |
| OASIS 1 (PMID 37385278) | Oral Semaglutide | 50 mg/day | 68 weeks | -15.1% |
Storage Guidelines
- Brand-Name Pens (Wegovy, Mounjaro)
- Refrigerate at 2-8°C before first use
- After first use: room temp for up to 56 days (Mounjaro) or 28 days (Wegovy)
- Protect from light and heat (>86°F/30°C)
- Do not freeze after reconstitution
- Compounded Vials
- Unreconstituted: freezer (-20°C) for long-term, fridge for 6+ months
- Reconstituted: always refrigerate at 2-8°C
- Use within 28 days of adding BAC water
- Discard if solution is cloudy or discolored
Frequently Asked Questions
Common questions
10 answersCan I skip dose escalation steps?
Not recommended. Skipping steps significantly increases the risk of severe nausea, vomiting, and other GI side effects. The escalation schedule exists because clinical trials found it necessary for tolerability.
What if I miss a dose during escalation?
If fewer than 5 days have passed (semaglutide), take the missed dose immediately. If more than 5 days have passed, skip it and continue on your regular schedule. Do not double-dose.
Is semaglutide or tirzepatide more effective?
Head-to-head data from the SURPASS clinical program suggests tirzepatide achieves greater weight loss (~22.5% vs ~14.9%). However, individual responses vary and the best choice depends on a patient's medical history and tolerability.
Can I use the same vial across escalation steps?
Yes. With compounded peptides, you can use the same reconstituted vial and simply adjust the number of syringe units drawn for each dose step. However, the vial must be used within 28 days of reconstitution.
When will retatrutide be FDA-approved?
Retatrutide is in Phase III clinical trials (TRIUMPH program). If results are positive, FDA filing is expected in late 2025/2026 with potential approval in 2026/2027.
Can I take oral semaglutide (Rybelsus) for weight loss?
Rybelsus is FDA-approved for type 2 diabetes only, not weight management. However, a higher-dose oral formulation (50 mg) is under investigation for obesity. The current max dose (14 mg/day) has shown modest but clinically meaningful weight loss.
How much does compounded semaglutide cost vs brand?
Compounded semaglutide typically costs $100-300/month vs $1,300-1,600/month for Wegovy without insurance. However, compounded products are not FDA-approved and quality varies by pharmacy. Always verify you're using a licensed 503B compounding pharmacy.
What happens if I skip the titration and start at a high dose?
Severe, sometimes debilitating GI side effects: persistent nausea, sulfur burps, vomiting, and profuse diarrhea. GLP-1 receptors need time to upregulate tolerance to gastric motility suppression. Titration is non-negotiable.
Can I split my weekly GLP-1 dose into twice-weekly injections?
The labels give these medicines once weekly. Splitting a weekly dose has not been tested in a published trial, so it is off-label; ask your prescriber before changing how you take it.
What is the difference between semaglutide and tirzepatide for weight loss?
Tirzepatide targets both GLP-1 and GIP receptors (dual agonist), producing significantly greater average weight loss (~22% body weight) compared to semaglutide (~15%). Its broader mechanism benefits body composition more aggressively.
Medical disclaimer: This guide is for educational purposes only. Consult a licensed healthcare provider before starting, stopping, or changing any GLP-1 agonist.
References
Sources cited in this article
2 sources- 1Once-weekly semaglutide in adults with overweight or obesity (STEP 1)Wilding JPH, et al., N Engl J Med 2021 · PMID: 33567185
- 2Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)Jastreboff AM, et al., N Engl J Med 2022 · PMID: 35658024